Healthcare Industry News: Sutent
News Release - December 2, 2009
Tom Anderton Joins Presidio Pharmaceuticals, Inc. as Vice President of Intellectual Property and Legal AffairsSAN FRANCISCO--(HSMN NewsFeed)--Presidio Pharmaceuticals, Inc. is pleased to announce that Tom Anderton has joined the Company as Vice President of Intellectual Property and Legal Affairs.
“Tom’s expertise in developing an IP portfolio in the biopharma space will be critical to Presidio’s development,” said Omar Haffar, President and CEO. “Having Tom join Presidio’s management team builds significant value for the company and our investors. All of us at Presidio look forward to working with Tom and the rest of the team to build a strong and integrated company.”
Tom was previously Associate General Counsel at Monogram Biosciences, Inc., where he was responsible for many general legal affairs as well as developing and implementing the IP portfolio related to oncology and virology. Prior to Monogram, Tom was the Lead Attorney, Oncology at Genencor, Inc. where he developed and implemented Genencor’s oncology IP portfolio and led legal affairs for Health Care. Previously, Tom created the patent strategy and portfolio related to SUGEN’s virtual ‘kinome’ IP portfolio and was also instrumental in developing the portfolio that includes the current Pfizer compound Sutent.
Tom earned his B.S. in Molecular Biology at UCSD, and subsequently entered Stanford University, where he received his M.S. in Cancer Biology. Tom went on to attend law school and earned his J.D. at the Vermont Law School. Tom is a member of the State Bar of California and is registered to practice before the United States Patent and Trademark Office.
“I am very excited about joining Presidio Pharmaceuticals,” commented Mr. Anderton. “Presidio has an amazing group of people working on promising new therapies to treat diseases that affect millions of people worldwide. I look forward to contributing to the continued success of the company by leading Presidio’s legal function and by building the IP portfolio around Presidio’s therapies.”
Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, in-licensing, development and commercialization of novel therapeutics for viral infections, including HIV-1 and HCV. For more information, please visit our website at www.presidiopharma.com.
Source: Presidio Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.